Ireland
--:--IST
Clinical Trials in the EU / 2025-521828-30-00
Authorised, recruiting Phase I/II

Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors

2025-521828-30-00 · tracked via the Priya Life Science EU tracker
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
19/11/2025
Enrollment target
21
Sites
France, Spain, Poland

Condition studied

Advanced Solid Tumors

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521828-30-00 on CTIS ↗ ← All trials in the EU